Skip to main content


  • ePoster presentation
  • Open Access

Alphalinolenic acid, a potent inhibitor of fatty acid synthase antimycobacterial agent

  • 1,
  • 1Email author,
  • 1,
  • 1 and
  • 1
BMC Infectious Diseases201414 (Suppl 3) :E19

  • Published:


  • Linolenic Acid
  • Minimum Inhibitory Concentration
  • Potent Inhibitor
  • Isoniazid
  • Mycobacterium Tuberculosis


The mycobacteria become resistant since their slow growth phase increases its ability to adapt and acquire new resistance mechanisms. Presently the first line therapy against TB includes the use of isoniazid and rifampin, which are probably the most effective mycobacterial drugs available today and then there is a very small chance to treat the disease since other newer drugs are seriously limited by gastrointestinal, renal and/or neurological toxicities. Therefore, the search for new ways to treat TB is of primary importance and urgency. Alphalinolenic acid (ALA) is a potent inhibitor of fatty acid synthase (FAS) in a variety of prokaryotic and eukaryotic cells.


Using a standardized mycobacterial susceptibility test, we have observed that ALA inhibits the growth of several species of mycobacteria, including tuberculous species such as Mycobacterium tuberculosis (H37Rv and clinical isolates) and Mycobacterium bovis BCG.


Alpha linolenic acids are toxic to mycobacteria, such as Mycobacterium tuberculosis H37Rv, with minimum inhibitory concentrations (MICs) of 25-50 μg/mL and Mycobacterium bovis with minimum inhibitory concentration of 6.25 – 25 μg/mL.


Our data demonstrate that ALA as a prototypical inhibitor, significant antimycobactericidal effects was seen with Mycobacterium tuberculosis and Mycobacterium bovis. A possible antibacterial mechanism was postulated to proceed via disruption of the bacterial cell membrane resulting in a change in membrane permeability.

Authors’ Affiliations

Department of Biomedical Engineering, Sri Siva Subramaniya Nadar College of Engineering, Kalavakkam, Chennai, 603110, India


© Jainu et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.